Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fgl2 circular RNA lipid nanoparticle
- Development stage
- Preclinical
- Lead developer
- Harvard Medical School
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Parenteral
01
Overview
Fgl2 circular RNA lipid nanoparticle is an investigational circular RNA (circRNA) therapeutic encapsulated in lipid nanoparticles (LNPs) designed to achieve systemic overexpression of circulating fibrinogen-like protein 2 (Fgl2) [A063]. Fgl2 is an immunomodulatory molecule secreted by CD8+ regulatory T cells that plays a key role in the establishment and maintenance of spontaneous transplant tolerance (defensive tolerance) [A063]. By delivering circRNA encoding either the soluble Fgl2 (sFgl2) fibrinogen-related domain (FRED) or the full-length membrane-bound Fgl2 (mFgl2) coding region, the therapy aims to prolong allograft survival and prevent transplant rejection [A063]. In preclinical murine models of abdominal cardiac transplantation, systemic administration of Fgl2 RNA-LNPs significantly increased circulating Fgl2 protein levels and prolonged allograft survival [A063].
- Other names
- Fgl2 RNA-LNPFgl-2 RNA-LNPFgl 2 RNA-LNPFgl2 RNA-LNPsFgl-2 RNA-LNPsFgl 2 RNA-LNPsFgl2-encoding circular RNA encapsulated in lipid nanoparticlesFgl-2-encoding circular RNA encapsulated in lipid nanoparticlesFgl 2-encoding circular RNA encapsulated in lipid nanoparticles
02
Targets
FCGR2B (Fc gamma receptor IIB)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)FGL2 (Fibrinogen-like protein 2)
Beyond the preview
Go deeper on Fgl2 circular RNA lipid nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fgl2 circular RNA lipid nanoparticle.